Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.54 USD | -2.37% | -4.22% | +6.57% |
May. 07 | Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Transcript : Inozyme Pharma, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 281M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.86
x | P/E ratio 2025 * |
-2.84
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.21% |
Latest transcript on Inozyme Pharma, Inc.
1 day | -2.37% | ||
1 week | -4.22% | ||
Current month | +2.95% | ||
1 month | -13.03% | ||
3 months | -21.99% | ||
6 months | +56.55% | ||
Current year | +6.57% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Director of Finance/CFO | 48 | 22-03-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Reinaldo Diaz
BRD | Director/Board Member | 70 | 16-12-31 |
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 4.54 | -2.37% | 323,256 |
24-05-09 | 4.65 | +0.22% | 460,487 |
24-05-08 | 4.64 | +0.87% | 392,062 |
24-05-07 | 4.6 | -5.74% | 558,178 |
24-05-06 | 4.88 | +2.95% | 354,520 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.57% | 281M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- INZY Stock